Literature DB >> 11142428

On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions.

M L Carlsson1.   

Abstract

OBJECTIVE: The objective of the present study was to compare the phenomenology and pathophysiology of obsessive-compulsive disorder (OCD) and attention-deficit hyperactivity disorder/deficits in attention, motor control and perception (ADHD/DAMP).
METHOD: Through detailed studies of the literature on OCD and ADHD/DAMP the phenomenology of these two conditions is compared, and possible underlying pathophysiological mechanisms involving interactions between glutamate, dopamine, serotonin and acetylcholine are discussed, with emphasis on OCD. The present paper also discusses possible mechanisms of action for current pharmacological treatments of OCD and ADHD, as well as possible future treatment strategies for these disorders.
RESULTS: OCD and ADHD/DAMP are common neuropsychiatric conditions which in many regards appear to be each other's antipodes with respect to clinical manifestations, associated personality traits and brain biochemistry, notably prefrontal cortical glutamate activity. Future pharmacological treatments of these disorders may involve manipulations with glutamate, dopamine D1, serotonin 2A and nicotine receptors.
CONCLUSION: It appears that OCD is a hyperglutamatergic and ADHD a hypoglutamatergic condition, with prefrontal brain regions being especially affected.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11142428     DOI: 10.1034/j.1600-0447.2000.102006401.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  28 in total

1.  Glutamate system genes associated with ventral prefrontal and thalamic volume in pediatric obsessive-compulsive disorder.

Authors:  Paul Daniel Arnold; Frank P Macmaster; Gregory L Hanna; Margaret A Richter; Tricia Sicard; Eliza Burroughs; Yousha Mirza; Phillip C Easter; Michelle Rose; James L Kennedy; David R Rosenberg
Journal:  Brain Imaging Behav       Date:  2009-03-01       Impact factor: 3.978

2.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

3.  Temperamental factors in children and adolescents with obsessive-compulsive disorder (OCD) and in normal controls.

Authors:  Tord Ivarsson; Catharina Winge-Westholm
Journal:  Eur Child Adolesc Psychiatry       Date:  2004-12       Impact factor: 4.785

4.  Differential neuroimaging indices in prefrontal white matter in prenatal alcohol-associated ADHD versus idiopathic ADHD.

Authors:  Joseph O'Neill; Mary J O'Connor; Victor Yee; Ronald Ly; Katherine Narr; Jeffrey R Alger; Jennifer G Levitt
Journal:  Birth Defects Res       Date:  2019-01-29       Impact factor: 2.344

5.  Treatment Efficacy of Combined Sertraline and Guanfacine in Comorbid Obsessive-Compulsive Disorder and Attention Deficit/Hyperactivity Disorder: Two Case Studies.

Authors:  Shibany P Taormina; Matthew P Galloway; David R Rosenberg
Journal:  J Dev Behav Pediatr       Date:  2016 Jul-Aug       Impact factor: 2.225

Review 6.  Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.

Authors:  C Mehler-Wex; P Riederer; M Gerlach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 7.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

8.  Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907.

Authors:  Helen Blair Simpson; Mark Slifstein; James Bender; Xiaoyan Xu; Elizabeth Hackett; Michael J Maher; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2011-11-01       Impact factor: 13.382

9.  Disorder-specific dysfunction in right inferior prefrontal cortex during two inhibition tasks in boys with attention-deficit hyperactivity disorder compared to boys with obsessive-compulsive disorder.

Authors:  Katya Rubia; Ana Cubillo; Anna B Smith; James Woolley; Isobel Heyman; Michael J Brammer
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

Review 10.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.